FDA Approves Bimekizumab for Three Rheumatologic Conditions
The US Food and Drug Administration has approved bimekizumab-bkzx (Bimzelx; UCB) for adult patients with active psoriatic arthritis (PsA), active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and active ankylosing spondylitis (AS). The drug, an interleukin (IL)-17A and IL-17F inhibitor, was first approved in October 2src23 for treatment of moderate to severe plaque
The US Food and Drug Administration has approved bimekizumab-bkzx (Bimzelx; UCB) for adult patients with active psoriatic arthritis (PsA), active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and active ankylosing spondylitis (AS). The drug, an interleukin (IL)-17A and IL-17F inhibitor, was first approved in October 2src23 for treatment of moderate to severe plaque …
Read More
About Author
